Oral PDE-4 Inhibitor, OTEZLA®, Approved for the Treatment of Plaque Psoriasis and ...

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that OTEZLA^® (apremilast), Celgene's oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full marketing authorization by Japan's Ministry of Health, Labor and Welfare (MHLW) for the treatment of adult patients with plaque psoriasis with an inadequate response to topical therapies, as well as adult patients with psoriatic arthritis.

“The approval of the first oral treatment in 25 years for psoriasis is good news. OTEZLA^® has a novel mechanism of action, is well tolerated and does not require monitoring before administration. We are pleased that OTEZLA^® presents a new treatment option for patients,” said Mamitaro Ohtsuki, M.D., Ph.D., Professor and Chairman, Department of Dermatology, Jichi Medical University. ...

Source : http://me-newswire.net//news/19258/en...